Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009



    VANCOUVER, Aug. 6 /CNW/ - Angiotech Pharmaceuticals, Inc. (NASDAQ:   ANPI,
TSX: ANP) today announced its financial results for the second quarter ended
June 30, 2009.
    "We were pleased to observe continued sales growth in our Proprietary
Medical Products business during the quarter, including continued acceleration
of our important Quill(TM) SRS and HemoStream(TM) product lines," said Dr.
William Hunter, President and CEO of Angiotech. "Despite the continued
challenges we are experiencing in certain parts of our Base Medical Products
business, the continued stabilization of our TAXUS(R)-derived royalty revenue,
the possibility that Cook's Zilver(TM) paclitaxel-eluting peripheral stent may
contribute additional royalty revenue and the recent FDA approval of our
Option(TM) Inferior Vena Cava Filter leave us optimistic about the second half
of 2009 and 2010."

    
    Second Quarter Financial Highlights

    -   Total revenue was $64.6 million.

    -   Net product sales were $47.2 million. Sales of our Proprietary
        Medical Products were $13.5 million, or 29% of total product sales.
        Sales of our Base Medical Products were $33.7 million, or 71% of
        total product sales.

    -   Royalty revenue was $17.0 million.

    -   Adjusted EBITDA (earnings before interest, taxes, depreciation and
        amortization, adjusted to exclude certain non-cash and non-recurring
        items) was $12.6 million.

    -   Research and development expenses were $6.8 million, and as adjusted
        to exclude non-cash stock-based compensation expenses and other non-
        recurring costs were $6.1 million.

    -   Selling, general and administrative expenses were $21.6 million, and
        as adjusted to exclude non-cash stock-based compensation expenses,
        certain litigation costs, non-recurring financing fees and other non-
        recurring costs were $19.0 million.

    -   GAAP net loss and net loss per share for the quarter were ($11.9)
        million and ($0.14), respectively.

    -   Adjusted net loss and adjusted net loss per share for the quarter
        were ($1.8) million and ($0.02), respectively.

    -   As of June 30, 2009, cash and short-term investments were $52.3
        million and net debt was $522.7 million.
    

    Second Quarter Highlights

    Proprietary Medical Products. Certain of our product lines, which we
refer to as our Proprietary Medical Products, are marketed and sold by our two
direct sales groups. We believe certain of these product lines contain
technology advantages that may provide for more substantial revenue growth
potential as compared to our overall product portfolio. Our significant
currently marketed Proprietary Medical Products include (i) our Quill(TM) SRS
wound closure product line, which is marketed and sold by our Surgical
Products Sales Group, and (ii) our HemoStream(TM) dialysis catheter, our
Skater(TM) line of drainage catheters, our BioPince(TM) full core biopsy
device, our EnSnare(TM) retrieval device and our V+Pad(TM) hemostatic pad
which are marketed and sold by our Interventional Products Sales Group. Our
Proprietary Medical Products continued to demonstrate higher revenue growth as
compared to our overall product portfolio, consistent with recent prior
quarters. Revenue growth for these products in the second quarter of 2009 was
approximately 15% as compared to the second quarter of 2008 and 4% as compared
to the first quarter of 2009. Excluding the impact of foreign currency changes
between the respective periods, the revenue growth figures indicated above
would have been 21% and 3%, respectively.

    Base Medical Products. Certain of our product lines, which we refer to as
our Base Medical Products, represent more mature finished goods product lines
in the ophthalmology, biopsy and general surgery areas, or medical device
components manufactured by us and sold to other third-party medical device
manufacturers who assemble those components into finished medical devices.
Sales of our Base Medical Products are supported by a small group of direct
sales personnel, as well as a network of independent sales representatives and
medical product distributors. Sales of our Base Medical Products tend to
exhibit greater volatility or slower relative growth, particularly our sales
of components to third party medical device manufacturers, which may be
impacted by customer concentration and the business issues that certain of our
large customers may face, as well as to a more limited extent by economic and
credit market conditions. Sales of our Base Medical Products declined by
approximately 13% in the second quarter of 2009 as compared to the second
quarter of 2008, and increased by approximately 2% as compared to the first
quarter of 2009. Excluding the impact of foreign currency changes, revenue
would have declined by 10% as compared to the second quarter of 2008. Foreign
currency fluctuations did not have an impact on the change from the first
quarter of 2009.
    The decline in our Base Medical Products sales as compared to the second
quarter of 2008 is due primarily to lower sales of medical device components
to other third party medical device manufacturers, generally relating to
certain customers that have postponed or cancelled orders, or implemented
inventory reduction programs in response to changing economic and credit
market conditions, and more particularly relating to cancelled orders for
surgical needles by one of our largest customers. Manufacturing of surgical
needles, as of November 2008, was fully transferred to our facility in
Aguadilla, Puerto Rico from our facility in Syracuse, New York. We believe
that the closure of our Syracuse production facility in November and the
finalization of our move of surgical needle production to Aguadilla, combined
with the difficult economic and credit market environment, may have negatively
impacted our Base Medical Product sales during the second quarter of 2009 as
compared to the second quarter of 2008. We currently expect that certain of
our customers may increase their order levels later in 2009, however, there
can be no assurance that we will record sales of surgical needles to these
customers at levels observed in prior periods.

    Royalty Revenue. We generate significant revenue derived from royalties
paid to us by partners that develop, market and sell products incorporating
certain of our proprietary technologies. Currently, our principal revenues in
this segment are from royalties derived from sales by Boston Scientific
Corporation ("BSC") of TAXUS(R) coronary stent systems incorporating the drug
paclitaxel. TAXUS stents have been evaluated by the industry's most extensive
randomized, controlled clinical trial program, with patient follow-up out to
five years in some cases. BSC's controlled clinical trial results have been
supplemented by data on more than 35,000 patients enrolled in post-approval
registries. To date, approximately 11 million TAXUS stents have been implanted
globally, making them the world's most frequently used coronary stents.
    Royalty revenue derived from sales of TAXUS stents by BSC for the second
quarter of 2009 decreased by 32% as compared to the second quarter of 2008.
The decrease in royalty revenues was a result of lower sales of TAXUS stents
by BSC, driven primarily by the entry of new competitors into the drug-eluting
coronary stent market during the second half of 2008. As compared to the first
quarter of 2009, our royalty revenue derived from sales of TAXUS stents
increased by 7.9%. The second quarter of 2009 represented the second
consecutive quarter where modest increases in our TAXUS-derived royalty
revenue were observed, indicating that sales levels for TAXUS may have
stabilized after several quarterly periods of significant decline.
    Royalty revenue for the second quarter of 2009 was based on BSC's net
sales for the period January 1, 2009 to March 31, 2009 of $252 million, of
which $119 million was in the United States, compared to net sales of $353
million for the second quarter of 2008, of which $195 million was in the
United States. The average gross royalty rate earned in the three month period
ended June 30, 2009 on BSC's net sales was 6.6% for sales in the United States
and 6.2% for sales in other countries.

    Option(TM) Inferior Vena Cava Filter. In June 2009, we announced that the
United States Food and Drug Administration ("FDA") had granted 510(k)
clearance for the Option(TM) Inferior Vena Cava ("IVC") Filter, for use in
both permanent and retrievable indications. We commenced commercial sales of
the Option IVC Filter in the United States in July 2009.
    IVC filters are implanted in patients that are at high risk for
developing pulmonary embolism, which can be a life threatening condition. IVC
filters are implanted in the inferior vena cava and are designed to catch clot
material to prevent it from reaching the lungs, while allowing blood to
continue to flow normally. Patients at high risk for pulmonary embolism are
typically patients undergoing a significant surgical procedure, trauma
patients or patients that have experienced a previous embolic event. IVC
filters have been shown in several studies to significantly reduce the risk of
pulmonary embolism and related mortality in certain high risk patient
populations. In certain cases, once the risk of an embolic event has passed,
the IVC filter will be removed in a subsequent surgical procedure. We believe
the Option IVC Filter may have a number of potential competitive benefits,
which include a unique filter design that may reduce the potential for filter
migration after implantation, thereby making the product safer for patients,
insertion potential through either the femoral or jugular route, which may
make the product easier for a physician to use, and the use of
non-thrombogenic material which reduces the risk of blood clots occurring in
the filter. We also believe the unique design of the Option IVC Filter may
allow physicians to remove or retrieve the device from patients more easily,
or after longer periods of time have passed as compared to existing
competitive IVC filters.
    The Option IVC Filter was approved based upon the results of a United
States multi-center prospective clinical trial. The purpose of the clinical
trial was to evaluate the device's safety and efficacy in preventing pulmonary
emboli, and to assess the ability to retrieve the device from the body up to
175 days following implantation. The results, representing a total of 100
patients, were presented at the 2009 Society of Interventional Radiology in
San Diego, CA on March 9, 2009. Successful filter implantation was achieved in
100% of the subjects and the retrieval rate in the study was 92.3%. Clinical
success, which was achieved in 88% of subjects, was defined as placement of
the filter without subsequent pulmonary embolism, significant filter migration
or embolization, symptomatic caval thrombosis or other complications requiring
filter removal or invasive intervention.
    The Option IVC Filter was licensed in March 2008 from our partner Rex
Medical L.P. ("Rex Medical"). We are obligated to pay royalties and milestone
payments to Rex Medical derived from our sales of the Option IVC Filter. We
made a milestone payment of $2.5 million to Rex Medical upon 510(k) clearance
of the Option IVC Filter during the second quarter of 2009 and recorded the
payment as an intangible asset.

    License, Distribution, Development and Supply Agreements with Haemacure
Corporation. In June 2009, we announced that we had entered into license,
distribution, development and supply agreements for fibrin and thrombin
technologies with Haemacure Corporation ("Haemacure"). The collaboration
provides us with access to technology for certain of our surgical product
candidates which are currently in preclinical development. As part of this
collaboration, we have agreed to provide to Haemacure a senior secured bridge
financing facility. The senior secured bridge loan will provide $2.5 million
to Haemacure in multiple draw-downs throughout 2009. The loan will be senior
to all of Haemacure's existing and future indebtedness, subject to certain
exceptions, will bear interest at an annual rate of 10%, compounded quarterly,
and will have a term of two years. We may, at our sole discretion, during a
period of two years, advance up to an additional $1 million to Haemacure from
time to time, in multiple draw-downs, for a total loan amount of $3.5 million.
The senior secured bridge loan also has certain equity conversion features and
rights to board representation upon conversion. As of June 30, 2009, $1.2
million of the loan has been drawn upon by Haemacure and a further $0.6
million of the loan, which had been accrued at June 30, 2009, was drawn upon
subsequent to June 30, 2009. Of the total of $1.8 million paid and accrued,
$1.2 million has been classified as other assets and $0.6 million has been
classified as prepaid expenses and other current assets.

    New TAXUS Regulatory Approvals and Clinical Data. In July 2009, we
announced that our partner BSC, had received approval from the FDA to market
its TAXUS Liberté Long(TM) paclitaxel-eluting coronary stent system, a
next-generation paclitaxel-eluting stent specifically designed for treating
more diffuse coronary artery disease with a single coronary stent. At 38 mm,
it is the longest available paclitaxel-eluting stent, providing physicians an
option that can potentially reduce the number of stents used in more complex
cases, simplifying procedures and reducing costs. It affords a more efficient
treatment option for the estimated 8 to 10 percent of patients with long
lesions. BSC plans to launch the product in the United States in August 2009.
In May 2009, we announced that our partner BSC, had received approval from the
FDA to market its TAXUS(R) Liberté(R) Atom(TM) paclitaxel-eluting coronary
stent system, a next-generation paclitaxel-eluting stent specifically designed
for treating small coronary vessels. It was approved for use in vessels as
small as 2.25 mm in diameter and joins the TAXUS Express Atom(TM) stent as the
only drug-eluting stents ("DES") approved for small vessel use in the United
States.
    In May 2009, we announced that our partner BSC had launched the platinum
chromium TAXUS Element(TM) paclitaxel-eluting coronary stent system in select
markets worldwide. The platinum chromium TAXUS Element paclitaxel-eluting
coronary stent system is the third-generation BSC coronary stent platform that
incorporates our research, technology and intellectual property related to the
use of paclitaxel. The TAXUS Element stent features BSC's proprietary platinum
chromium alloy, which is designed to enable thinner stent struts, increased
flexibility and a lower stent profile while improving radial strength, recoil
and radiopacity. In addition, the TAXUS Element stent platform incorporates
new balloon technology intended to improve upon BSC's market-leading
Maverick(R) balloon catheter technology.

    New Independent TAXUS Clinical Data. In May 2009 we announced that our
partner BSC had welcomed the publication of an article in the Journal of the
American College of Cardiology (JACC) reviewing data on more than 19,000
patients from the Swedish national registry who were evaluated for restenosis,
or the re-narrowing or arteries, after percutaneous coronary intervention
("PCI"). The Swedish Coronary Angiography and Angioplasty Registry holds data
on all patients undergoing PCI in Sweden. The objective of this independent
study was to evaluate restenosis rates of DES's in patients with and without
diabetes in a real-world setting. The article reported that patients who
received a TAXUS Liberté paclitaxel-eluting stent had numerically lower
incidences of repeat procedures to treat restenosis at two years as compared
to patients treated with 'olimus-based DES's, including Johnson & Johnson,
Inc.'s Cypher(R) Stent and Medtronic Inc.'s Endeavor(R) Stent.
    In the patients with diabetes, the TAXUS Liberté demonstrated a
statistically significant lower restenosis rate compared to the Endeavor,
which had more than two times the risk of repeat procedures. The JACC article
reported that both the TAXUS Liberté stent and BSC's first-generation
paclitaxel-eluting stent, the TAXUS Express, were the only stents in the study
showing no increased risk of restenosis for patients with diabetes as compared
to those without diabetes. Data for both the Cypher and Endeavor stents
indicated significant increased risk of restenosis in patients with diabetes.
In addition, the study showed that the TAXUS Liberté had an approximately 23
percent lower restenosis rate at two years compared to the prior-generation
TAXUS Express.
    The Swedish registry study included four DES brands: TAXUS Liberté, TAXUS
Express, Cypher and Endeavor. In total, the registry included 35,478 DES
implants during 22,962 procedures in 19,004 patients, with 1,807 restenoses
reported over a mean 29-month follow-up period. For the entire study
population, the repeat revascularization rate per stent was 3.5 percent after
one year and 4.9 percent after two years. Overall, the adjusted risk of
restenosis was 1.23 times higher in patients with diabetes than in patients
without diabetes. In patients with diabetes, restenosis was higher in the
non-TAXUS stents. The sirolimus-eluting Cypher and the zotorolimus-eluting
Endeavor had higher restenosis rates in patients with diabetes compared with
those in patients without diabetes (1.25 times and 1.77 times, respectively).

    New ZILVER(R) PTX(TM) Clinical Data. In April 2009 we announced that our
partner Cook Medical Inc. ("Cook") had reported data that showed that 82
percent of patients who were treated with Cook's ZILVER PTX paclitaxel-eluting
peripheral stent were free from reintervention at two-year follow up. The
ZILVER PTX Registry study, involving 792 patients globally, is assessing the
safety and efficacy of the ZILVER PTX in treating peripheral artery disease.
The most recent results were reported at the 31st International Symposium
Charing Cross Controversies Challenges Consensus. Data was compiled at 12 and
24 months for 593 patients and 177 patients respectively. The registry, which
enrolled a broad spectrum of patients, includes patients with complex lesions
(e.g., long lesions, total occlusions, in-stent restenosis). The corresponding
event-free survival rates were 87 percent and 78 percent, and freedom from
target lesion revascularization was 89 percent and 82 percent. Clinical
measures that included ankle-brachial index, Rutherford score, and walking
distance and speed scores showed significant improvement at six and 12 months
and were maintained through 24 months. Detailed evaluation of stent x-rays
demonstrated excellent stent integrity through 12 months, confirming
previously published results showing 99 percent completely intact stents (less
than 1 percent stent fracture rates observed) with a mean follow up of 2.4
years in the challenging superior femoral artery and popliteal arteries,
including behind the knee locations.

    
    Financial Information
    ---------------------
    

    This press release contains financial data derived from the condensed
financial statements derived from the unaudited consolidated interim financial
statements for the three-month periods ended June 30, 2009, and 2008. Full
unaudited consolidated interim financial statements and Management's
Discussion and Analysis for the three-month periods ended June 30, 2009 and
2008 will be filed with the relevant regulatory agencies, as well as posted on
our website at www.angiotech.com.
    Amounts, unless specified otherwise, are expressed in U.S. dollars.
Financial results are reported under U.S. Generally Accepted Accounting
Principles ("GAAP") unless otherwise noted. All per share amounts are stated
on a diluted basis unless otherwise noted.

    
    Use of Certain Non-GAAP Financial Measures
    ------------------------------------------
    

    Certain financial results presented in this press release include
non-GAAP measures that exclude certain items. Adjusted net income (loss),
adjusted net income (loss) per share and adjusted earnings before interest,
taxes, depreciation and amortization ("Adjusted EBITDA") exclude certain
non-cash and non-recurring items such as, financing charges, write downs,
acquisition related amortization charges, acquired in-process research and
development relating to license agreements and acquisitions, stock-based
compensation expense, foreign exchange gains or losses relating to translation
of foreign denominated items and other non-recurring items. Adjusted net
income (loss), adjusted net income (loss) per share and Adjusted EBITDA also
exclude litigation expenses related to defending intellectual property claims.
Revenue, as adjusted, excludes non-recurring, non-operating revenue derived
from license agreements and other license revenue, net of license fees due to
licensors and excludes amounts accrued for costs incurred. Adjusted net income
(loss), adjusted net income (loss) per share, revenue, as adjusted, and
Adjusted EBITDA do not have any standardized meaning prescribed by GAAP and
therefore may not be comparable to similar measures presented by other
issuers. Management uses these non-GAAP or adjusted operating measures to
establish operational goals and believes that these measures may assist
investors in evaluating the results of the business and analyzing the
underlying trends in our business over time. Investors should consider these
non-GAAP measures in addition to, not as a substitute for, or as superior to,
financial reporting measures prepared in accordance with GAAP. We have
provided a reconciliation of these measures to GAAP in the attached tables.

    
    Conference Call Information
    ---------------------------

    A conference call to discuss these financial results will be held today,
Thursday August 6, 2009 at 8:00 AM PT (11:00 AM ET).

    Dial-in information:
    North America (toll-free): (866) 700-6067
    International: (617) 213-8834
    Enter Passcode: 91816046

    An archived replay of the call will be available until August 13, 2009.
    North America (toll-free): (888) 286-8010
    International: (617) 801-6888
    Enter Passcode: 23483326

    A live webcast will be available to all interested parties through the
Investors section of Angiotech's website: www.angiotech.com



                       ANGIOTECH PHARMACEUTICALS, INC.
                 CONDENSED CONSOLIDATED STATEMENTS OF INCOME
                                 (Unaudited)


    (in thousands of U.S.$, except                Three months ended
     share and per share data)                      June 30, 2009
    -------------------------------------------------------------------------
                                         Reported   Adjustments     Adjusted

    REVENUE
    Royalty revenue                    $   16,996   $      -      $   16,996
    Product sales, net                     47,179          -          47,179
    License fees                              398        (398) a           -
    --------------------------------- ---------------------------------------
                                           64,573        (398)        64,175
    --------------------------------- ---------------------------------------

    EXPENSES
    License and royalty fees                2,568           -          2,568
    Cost of products sold                  25,682        (896) b      24,786
    Research and development                6,833        (739) c       6,094
    Selling, general and administrative    21,606      (2,548) d      19,058
    Depreciation and amortization           8,296      (7,453) e         843
    --------------------------------- ---------------------------------------
                                           64,985     (11,636)        53,349
    --------------------------------- ---------------------------------------
    Operating (loss) income                  (412)     11,238         10,826
    --------------------------------- ---------------------------------------

    Other income (expenses):
    Foreign exchange (loss) gain           (1,441)      1,441  f           -
    Investment and other income (loss)       (600)        636  g          36

    Loss on sale/write-down of
     investments                                -           -              -
    Interest expense on long-term debt     (9,641)        750  i      (8,891)
    --------------------------------- ---------------------------------------
    --------------------------------- ---------------------------------------
                                          (11,682)      2,827         (8,855)
    --------------------------------- ---------------------------------------
    --------------------------------- ---------------------------------------

    (Loss) income before income taxes     (12,094)     14,065          1,971
    Income tax (recovery) expense            (217)      3,960  j       3,743
    --------------------------------- ---------------------------------------
    --------------------------------- ---------------------------------------

    Net loss for the period               (11,877)     10,105         (1,772)
    --------------------------------- ---------------------------------------

    Basic and diluted net loss per
     common share                      $    (0.14)                $    (0.02)
    --------------------------------- ---------------------------------------
    --------------------------------- ---------------------------------------

    Weighted average shares
     outstanding (000's) - basic &
     diluted                               85,122                     85,122
    --------------------------------- ---------------------------------------
    --------------------------------- ---------------------------------------



    (in thousands of U.S.$, except                Three months ended
     share and per share data)                      June 30, 2008
    -------------------------------------------------------------------------
                                         Reported   Adjustments    Adjusted

    REVENUE
    Royalty revenue                    $   25,536   $       -     $   25,536
    Product sales, net                     50,533           -         50,533
    License fees                               53         (53) a           -
    --------------------------------- ---------------------------------------
                                           76,122         (53)        76,069
    --------------------------------- ---------------------------------------

    EXPENSES
    License and royalty fees                3,661           -          3,661
    Cost of products sold                  26,809         (28) b      26,781
    Research and development               18,584      (1,366) c      17,218
    Selling, general and administrative    25,813      (2,167) d      23,646
    Depreciation and amortization           8,539      (7,593) e         946
    --------------------------------- ---------------------------------------
                                           83,406     (11,154)        72,252
    --------------------------------- ---------------------------------------
    Operating (loss) income                (7,284)     11,101          3,817
    --------------------------------- ---------------------------------------

    Other income (expenses):
    Foreign exchange (loss) gain              140        (140) f           -
    Investment and other income (loss)        686          12  g         698

    Loss on sale/write-down of
     investments                          (10,660)     10,660  h           -
    Interest expense on long-term debt    (10,941)        559  i     (10,382)
    --------------------------------- ---------------------------------------
    --------------------------------- ---------------------------------------
                                          (20,775)     11,091         (9,684)
    --------------------------------- ---------------------------------------
    --------------------------------- ---------------------------------------

    (Loss) income before income taxes     (28,059)     22,192         (5,867)
    Income tax (recovery) expense          (1,988)      3,563  j       1,575
    --------------------------------- ---------------------------------------
    --------------------------------- ---------------------------------------

    Net loss for the period               (26,071)     18,629         (7,442)
    --------------------------------- ---------------------------------------

    Basic and diluted net loss per
     common share                      $    (0.31)                $    (0.09)
    --------------------------------- ---------------------------------------
    --------------------------------- ---------------------------------------

    Weighted average shares
     outstanding (000's) - basic &
     diluted                               85,122                     85,122
    --------------------------------- ---------------------------------------
    --------------------------------- ---------------------------------------

    a.  Non-recurring and non-operating license revenue.
    b.  Non-recurring manufacturing variances, primarily related to excess
        labour costs incurred and to certain inventory write-downs resulting
        from cancellations of orders by a significant customer of our
        surgical needles business. Adjustments for the 2008 period relate to
        non-recurring supply/distribution agreement termination costs.
    c.  Research and development adjustments:
        ---------------------------------------------------------------------
                                                 Three months   Three months
                                                     ended          ended
                                                 Jun 30, 2009   Jun 30, 2008
                                                 ----------------------------
        Stock-based compensation                     $   (114)      $   (189)
        Termination and reorganization costs                -           (677)
        Non-recurring research and development
         expenses and intellectual property
         license agreement related to our
         termination agreements with Lipose Corp.
         and Spartan Medical Products LLC.               (625)          (500)
        ---------------------------------------------------------------------
                                                     $   (739)      $ (1,366)
                                                 ----------------------------

    d.  Selling, general and administrative adjustments:
        ---------------------------------------------------------------------
                                                 Three months   Three months
                                                     ended          ended
                                                 Jun 30, 2009   Jun 30, 2008
                                                 ----------------------------
        Stock-based compensation                     $   (309)      $   (418)
        Termination and reorganization costs             (332)        (1,026)
        Litigation expenses                            (1,494)          (691)
        Non-recurring transaction fees                   (413)           (32)
        ---------------------------------------------------------------------
                                                     $ (2,548)      $ (2,167)
                                                 ----------------------------

    e.  Amortization of acquisition related intangible assets and medical
        technologies.
    f.  Foreign exchange fluctuations on foreign currency net monetary
        assets.
    g.  Loss on write-down of deferred financing charges and realized loss on
        disposition of capital assets.
    h.  Loss on write-down of investments related to two available-for-sale
        equity securities that had been trading below carrying value for a
        prolonged period of time.
    i.  Amortization of deferred financing costs.
    j.  Tax effects of adjustments a. through i. for the period.



                       ANGIOTECH PHARMACEUTICALS, INC.
                 CONDENSED CONSOLIDATED STATEMENTS OF INCOME
                                 (Unaudited)

    (in thousands of U.S.$, except                Six months ended
     share and per share data)                      June 30, 2009
    -------------------------------------------------------------------------
                                         Reported   Adjustments     Adjusted

    REVENUE
    Royalty revenue                    $   34,107   $       -     $   34,107
    Product sales, net                     93,316           -         93,316
    License fees                           25,450     (25,450) a           -
    --------------------------------- ---------------------------------------
                                          152,873     (25,450)       127,423
    --------------------------------- ---------------------------------------

    EXPENSES
    License and royalty fees                5,474           -          5,474
    Cost of products sold                  49,648        (896) b      48,752
    Research and development               12,930      (1,152) c      11,778
    Selling, general and administrative    41,178      (5,131) d      36,047
    Depreciation and amortization          16,560     (14,834) e       1,726
    In-process research and development         -           -              -
    --------------------------------- ---------------------------------------
                                          125,790     (22,013)       103,777
    --------------------------------- ---------------------------------------
    Operating income (loss)                27,083      (3,437)        23,646
    --------------------------------- ---------------------------------------

    Other income (expenses):
    Foreign exchange (loss) gain             (709)        709  g           -
    Investment and other income (loss)       (615)        676  h          61
    Loss on sale/write-down of
     investments                                -           -              -
    Interest expense on long-term debt    (19,685)      1,368  j     (18,317)
    --------------------------------- ---------------------------------------
    --------------------------------- ---------------------------------------
                                          (21,009)      2,753        (18,256)
    --------------------------------- ---------------------------------------
    --------------------------------- ---------------------------------------

    Income (loss) before income taxes       6,074        (684)         5,390
    Income tax expense (recovery)           5,507         765  k       6,272
    --------------------------------- ---------------------------------------
    --------------------------------- ---------------------------------------
    Net income (loss) for the period   $      567   $  (1,449)    $     (882)
    --------------------------------- ---------------------------------------

    Basic and diluted net income
     (loss) per common share           $     0.01                 $    (0.01)
    --------------------------------- ---------------------------------------
    --------------------------------- ---------------------------------------

    Weighted average shares
     outstanding (000's) - basic and
     diluted                               85,122                     85,122
    --------------------------------- ---------------------------------------


    (in thousands of U.S.$, except                Six months ended
     share and per share data)                      June 30, 2008
    -------------------------------------------------------------------------
                                         Reported   Adjustments     Adjusted

    REVENUE
    Royalty revenue                    $   54,465   $        -    $   54,465
    Product sales, net                     98,259            -        98,259
    License fees                              106         (106) a          -
    --------------------------------- ---------------------------------------
                                          152,830         (106)      152,724
    --------------------------------- ---------------------------------------

    EXPENSES
    License and royalty fees                8,032            -         8,032
    Cost of products sold                  52,658          (28) b     52,630
    Research and development               34,889       (2,932) c     31,957
    Selling, general and administrative    53,654       (6,718) d     46,936
    Depreciation and amortization          17,017      (15,178) e      1,839
    In-process research and development     2,500       (2,500) f          -
    --------------------------------- ---------------------------------------
                                          168,750      (27,356)      141,394
    --------------------------------- ---------------------------------------
    Operating income (loss)               (15,920)      27,250        11,330
    --------------------------------- ---------------------------------------

    Other income (expenses):
    Foreign exchange (loss) gain              563         (563) g          -
    Investment and other income (loss)      1,442           12  h      1,454
    Loss on sale/write-down of
     investments                          (10,660)      10,660  i          -
    Interest expense on long-term debt    (23,061)       1,118  j    (21,943)
    --------------------------------- ---------------------------------------
    --------------------------------- ---------------------------------------
                                          (31,716)      11,227       (20,489)
    --------------------------------- ---------------------------------------
    --------------------------------- ---------------------------------------

    Income (loss) before income taxes     (47,636)      38,477        (9,159)
    Income tax expense (recovery)          (5,802)       7,961  k      2,159
    --------------------------------- ---------------------------------------
    --------------------------------- ---------------------------------------
    Net income (loss) for the period   $  (41,834)  $   30,516    $  (11,318)
    --------------------------------- ---------------------------------------

    Basic and diluted net income
     (loss) per common share           $    (0.49)                $    (0.13)
    --------------------------------- ---------------------------------------
    --------------------------------- ---------------------------------------

    Weighted average shares
     outstanding (000's) - basic and
     diluted                               85,114                     85,114
    --------------------------------- ---------------------------------------

    a.  One time payment from Baxter Healthcare Corporation in lieu of future
        royalty payments on licensed technology and non-recurring, non-
        operating license revenue.
    b.  Non-recurring manufacturing variances, primarily related to excess
        labour costs incurred and to certain inventory write-downs resulting
        from cancellations of orders by a significant customer of our
        surgical needles business. Adjustments for the 2008 period relate to
        non-recurring supply / distribution agreement termination costs.
    c.  Research and development adjustments:

        ---------------------------------------------------------------------
                                                  Six months     Six months
                                                     ended          ended
                                                 Jun 30, 2009   Jun 30, 2008
                                                 ----------------------------
        Stock-based compensation                     $   (215)      $   (500)
        Termination and reorganization costs                -         (1,307)
        Non-recurring research and development
         expenses and intellectual property
         license agreement related to our
         termination agreements with Lipose
         Corp. and Spartan Medical Products LLC.         (937)        (1,125)
        ---------------------------------------------------------------------
                                                     $ (1,152)      $ (2,932)
                                                 ----------------------------

    d.  Selling, general and administrative adjustments:

        ---------------------------------------------------------------------
                                                  Six months     Six months
                                                     ended          ended
                                                 Jun 30, 2009   Jun 30, 2008
                                                 ----------------------------
        Stock-based compensation                     $   (592)      $   (924)
        Termination and reorganization costs           (1,266)        (2,755)
        Litigation expenses                            (2,241)        (2,289)
        Non-recurring transaction fees, and
         supply/distribution agreement termination
         costs                                         (1,032)          (751)
        ---------------------------------------------------------------------
                                                     $ (5,131)      $ (6,718)
                                                 ----------------------------

    e.  Amortization of acquisition related intangible assets and medical
        technologies.
    f.  Non-recurring in-process research and development expense relating to
        payments made to licensors and collaborators.
    g.  Foreign exchange fluctuations on foreign currency net monetary
        assets.
    h.  Loss on write-down of deferred financing charges and realized loss on
        disposition of capital assets.
    i.  Loss on write-down of investments related to two available-for-sale
        equity securities that had been trading below carrying value for a
        prolonged period of time.
    j.  Amortization of deferred financing costs.
    k.  Tax effects of adjustments a. through j. for the period.


                       ANGIOTECH PHARMARCEUTICALS, INC.
                       CALCULATION OF ADJUSTED EBITDA
                                 (unaudited)

                                 Three months                 Six months
    (in thousands               ended June 30,              ended June 30,
     of U.S.$)                2009          2008          2009          2008
    -------------------- --------------------------- ------------------------
    Net (loss) income on
     a GAAP basis        $ (11,877)      (26,071)    $     567     $ (41,834)
    Interest expense on
     long-term debt          9,641        10,941        19,685        23,061
    Income tax (recovery)
     expense                  (217)       (1,988)        5,507        (5,802)
    Depreciation and
     amortization            9,207         9,723        18,368        19,172
    -------------------- --------------------------- ------------------------
    EBITDA                   6,754        (7,395)       44,127        (5,403)
    Adjustments:
    Non-recurring revenue,
     net of license fees      (398)          (53)      (25,451)         (106)
    Abnormal manufacturing
     variances and
     inventory write-downs     896             -           896             -
    In-process research
     and development             -             -             -         2,500
    Non-recurring research
     and development           625             -           938           625
    Stock-based
     compensation              423           607           807         1,425
    Litigation expenses      1,494           691         2,241         2,289
    Foreign exchange loss
     (gain)                  1,441          (140)          709          (563)
    Investment and other
     income                    600          (686)          615        (1,442)
    Severance and
     restructuring             332         1,762         1,266         4,840
    Write off of
     capitalized costs           -           500             -           500
    Write-down / loss on
     redemption of
     investments                 -        10,660             -        10,660
    Non-recurring
     financing costs           413             -         1,032             -
    -------------------- --------------------------- ------------------------
    Adjusted EBITDA      $  12,580         5,946     $  27,180     $  15,325
    -------------------- --------------------------- ------------------------



                    CONDENSED CONSOLIDATED BALANCE SHEETS
                                 (Unaudited)

    As at                                              June 30,  December 31,
    (in thousands of U.S.$)                               2009          2008
    -------------------------------------------------------------------------
    ASSETS
    Cash and short-term investments                  $  52,315     $  39,800
    Accounts receivable                                 28,405        25,524
    Inventories                                         38,761        38,594
    Deferred income taxes                                3,520         3,820
    Other current assets                                 4,475         5,234
    -------------------------------------------------------------------------
    Total current assets                               127,476       112,972
    -------------------------------------------------------------------------
    Long-term investments                                1,561         1,561
    Assets held for sale                                 8,463         8,422
    Property and equipment, net                         47,293        49,108
    Intangible assets, net                             183,230       195,477
    Deferred financing costs                            12,398        11,363
    Other assets                                         1,899         6,294
    -------------------------------------------------------------------------
    Total assets                                     $ 382,320     $ 385,197
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------
    LIABILITIES AND SHAREHOLDERS' DEFICIT
    Current liabilities                              $  58,690     $  61,415
    Long-term debt                                     575,000       575,000
    Deferred income taxes                               37,863        40,577
    Other tax liabilities                                2,962         3,145
    Other long-term liabilities                          4,849         4,933
    Stockholders' deficit                             (297,044)     (299,873)
    -------------------------------------------------------------------------
    Total liabilities and stockholders' deficit      $ 382,320     $ 385,197
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------


    Forward Looking Statements
    --------------------------
    

    Statements contained in this press release that are not based on
historical fact, including without limitation statements containing the words
"believes," "may," "plans," "will," "estimates," "continues," "anticipates,"
"intends," "expects" and similar expressions, constitute "forward-looking
statements" within the meaning of the Private Securities Litigation Reform Act
of 1995 and constitute "forward-looking information" within the meaning of
applicable Canadian securities laws. All such statements are made pursuant to
the "safe harbor" provisions of applicable securities legislation.
Forward-looking statements may involve, but are not limited to, comments with
respect to our objectives and priorities for the remainder of 2009 and beyond,
our strategies or future actions, our targets, expectations for our financial
condition and the results of, or outlook for, our operations, research and
development and product and drug development. Such forward-looking statements
involve known and unknown risks, uncertainties and other factors that may
cause the actual results, events or developments to be materially different
from any future results, events or developments expressed or implied by such
forward-looking statements. Many such known risks, uncertainties and other
factors are taken into account as part of our assumptions underlying these
forward-looking statements and include, among others, the following: general
economic and business conditions in the United States, Canada and the other
regions in which we operate; market demand; technological changes that could
impact our existing products or our ability to develop and commercialize
future products; competition; existing governmental regulations and changes
in, or the failure to comply with, governmental regulations; availability of
financial reimbursement coverage from governmental and third-party payers for
products and related treatments; adverse results or unexpected delays in
pre-clinical and clinical product development processes; adverse findings
related to the safety and/or efficacy of our products or products sold by our
partners; decisions, and the timing of decisions, made by health regulatory
agencies regarding approval of our technology and products; the requirement
for substantial funding to conduct research and development, to expand
manufacturing and commercialization activities; and any other factors that may
affect our performance. In addition, our business is subject to certain
operating risks that may cause any results expressed or implied by the
forward-looking statements in this Quarterly Report on Form 10-Q to differ
materially from our actual results. These operating risks include: our ability
to attract and retain qualified personnel; our ability to successfully
complete pre-clinical and clinical development of our products; changes in our
business strategy or development plans; our failure to obtain patent
protection for discoveries; loss of patent protection resulting from
third-party challenges to our patents; commercialization limitations imposed
by patents owned or controlled by third parties; our ability to obtain rights
to technology from licensors; liability for patent claims and other claims
asserted against us; our ability to obtain and enforce timely patent and other
intellectual property protection for our technology and products; the ability
to enter into, and to maintain, corporate alliances relating to the
development and commercialization of our technology and products; market
acceptance of our technology and products; our ability to successfully
manufacture, market and sell our products; the availability of capital to
finance our activities; our ability to restructure and to service our debt
obligations; and any other factors referenced in our other filings with the
applicable Canadian securities regulatory authorities or the Securities and
Exchange Commission ("SEC"). For a more thorough discussion of the risks
associated with our business, see the "Risk Factors" section in our annual
report for the year ended December 31, 2008 filed with the SEC on Form 10-K,
and our quarterly report for the three months ended March 31, 2009 filed with
the SEC on Form 10-Q.
    Given these uncertainties, assumptions and risk factors, investors are
cautioned not to place undue reliance on such forward-looking statements.
Except as required by law, we disclaim any obligation to update any such
factors or to publicly announce the result of any revisions to any of the
forward-looking statements contained in this presentation to reflect future
results, events or developments.
    (C)2009 Angiotech Pharmaceuticals, Inc. All Rights Reserved.

    About Angiotech Pharmaceuticals

    Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and
medical device company with over 1,500 dedicated employees. Angiotech
discovers, develops and markets innovative treatment solutions for diseases or
complications associated with medical device implants, surgical interventions
and acute injury. To find out more about Angiotech (NASDAQ:   ANPI, TSX: ANP),
please visit our website at www.angiotech.com.





For further information:

For further information: DeDe Sheel, Investor Relations and Corporate
Communications, Angiotech Pharmaceuticals, Inc., (415) 293-4412,
dede.sheel@fd.com

Organization Profile

Angiotech Pharmaceuticals, Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890